Results from study with Xarelto to be presented at ASH 2009

Findings from the phase III EINSTEIN-Extension study will be presented in the Late Breaking Abstract Session on 8th December 2009 at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.

The study investigated the long-term benefits of 20 mg Xarelto
once-daily compared with placebo in the secondary prevention of recurrent symptomatic venous blood clots in approximately 1,200 patients with symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE).

These patients had already completed 6 or 12 months of anticoagulant therapy, either as part of their routine care for an acute episode of venous thromboembolism (VTE) or as a participant in the EINSTEIN-DVT or EINSTEIN-PE clinical trials, where patients received either Xarelto or a vitamin K antagonist.

To find out more, please click on the link below:

ASH